Cure8 research brief
This real-world multicenter study provides short-term effectiveness and safety data for upadacitinib in a difficult-to-treat Crohn’s population in China, which may inform treatment decisions and risk discussions.
Adults with Crohn’s disease, clinicians treating refractory IBD, patients considering JAK inhibitors, and researchers interested in real-world drug outcomes.
This study followed 151 patients given upadacitinib induction (45 mg daily for 12 weeks) then maintenance (15 mg daily). Clinical remission was reported at 47.0% at week 12 and 62.9% at week 24; endoscopic remission at week 24 was 28.1%.
Adverse events were reported during both induction and maintenance, including three serious events (venous thrombosis, perforation, hemorrhage) and two male reproductive–system–related events noted by the authors. The authors describe high drug persistence at 24 weeks (93.4%).
These results come from an observational, multicenter cohort in China and reflect real-world practice for a difficult-to-treat population.
Observational real-world cohorts can differ from randomized trials in selection, monitoring, and outcome assessment. Reported reproductive-related events and serious adverse events are notable but require further investigation and corroboration in other datasets.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
